Landscape assessment for gender neutral human papillomavirus vaccination recommendations including head and neck cancer burden data

CONCLUSION: The burden of HPV-related HNC in the general male population has been recognized by several Heatlth Technology Assessment (HTA) agencies and National Immunization Technical Advisory Groups (NITAGs) when evaluating HPV GNV programs. The assessments identified on GNV programs strongly indicate a cost-effective clinical benefit. Nevertheless, the epidemiological burden of HNC may have been underestimated in some countries due to limited data. Further research is crucial to obtain more robust data that will help address the information gap in epidemiological and economic burden of HPV-associated HNC in men.PMID:34452775 | DOI:10.1016/j.vaccine.2021.08.043
Source: Vaccine - Category: Allergy & Immunology Authors: Source Type: research